SG Americas Securities LLC Lowers Holdings in Dynavax Technologies Corporation (NASDAQ:DVAX)

SG Americas Securities LLC reduced its stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 33.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,974 shares of the biopharmaceutical company's stock after selling 25,550 shares during the quarter. SG Americas Securities LLC's holdings in Dynavax Technologies were worth $674,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Deep Track Capital LP increased its stake in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after purchasing an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock valued at $66,325,000 after acquiring an additional 5,172,263 shares during the period. Norges Bank acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $7,762,000. D. E. Shaw & Co. Inc. increased its position in shares of Dynavax Technologies by 34.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after acquiring an additional 486,981 shares during the period. Finally, WINTON GROUP Ltd increased its position in shares of Dynavax Technologies by 339.0% in the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock valued at $5,450,000 after acquiring an additional 329,579 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Performance

NASDAQ:DVAX traded down $0.31 during mid-day trading on Friday, hitting $9.99. The company's stock had a trading volume of 5,233,685 shares, compared to its average volume of 2,176,187. Dynavax Technologies Corporation has a 1 year low of $9.22 and a 1 year high of $14.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -19.21 and a beta of 1.06. The business's fifty day moving average is $10.30 and its two-hundred day moving average is $12.06.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The business had revenue of $68.16 million during the quarter, compared to analysts' expectations of $70.01 million. Analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DVAX has been the topic of several research reports. The Goldman Sachs Group cut their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. JMP Securities cut their target price on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Dynavax Technologies presently has a consensus rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.